CL2023003905A1 - Conjugados novedosos que comprenden fosfoantígenos y su uso terapéutico - Google Patents
Conjugados novedosos que comprenden fosfoantígenos y su uso terapéuticoInfo
- Publication number
- CL2023003905A1 CL2023003905A1 CL2023003905A CL2023003905A CL2023003905A1 CL 2023003905 A1 CL2023003905 A1 CL 2023003905A1 CL 2023003905 A CL2023003905 A CL 2023003905A CL 2023003905 A CL2023003905 A CL 2023003905A CL 2023003905 A1 CL2023003905 A1 CL 2023003905A1
- Authority
- CL
- Chile
- Prior art keywords
- phosphoantigen
- segment
- specific
- phosphoantigens
- conjugates
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000008685 targeting Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21182160 | 2021-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023003905A1 true CL2023003905A1 (es) | 2024-08-02 |
Family
ID=76695639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003905A CL2023003905A1 (es) | 2021-06-28 | 2023-12-26 | Conjugados novedosos que comprenden fosfoantígenos y su uso terapéutico |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240261426A1 (https=) |
| EP (1) | EP4362982A1 (https=) |
| JP (1) | JP2024524363A (https=) |
| KR (1) | KR20240027761A (https=) |
| CN (1) | CN117794581A (https=) |
| AU (1) | AU2022302784A1 (https=) |
| BR (1) | BR112023026735A2 (https=) |
| CA (1) | CA3223936A1 (https=) |
| CL (1) | CL2023003905A1 (https=) |
| IL (1) | IL309249A (https=) |
| MX (1) | MX2023014899A (https=) |
| WO (1) | WO2023275025A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120379696A (zh) | 2022-12-22 | 2025-07-25 | 拜奥迪斯私人有限公司 | 包含磷酸抗原的新的接头药物、新的缀合物及其在治疗中的用途 |
| WO2026080697A1 (en) * | 2024-10-09 | 2026-04-16 | Sutro Biopharma, Inc. | Antibody conjugates with high payload to antibody ratios, compositions comprising the same, and methods of their use |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| FI115001B (fi) | 2003-07-11 | 2005-02-15 | Metso Paper Inc | Menetelmä ja sovitelma rullan päätylapun sijainnin mittaamiseksi |
| JP4942643B2 (ja) | 2004-03-02 | 2012-05-30 | シアトル ジェネティックス， インコーポレイテッド | 部分的に付加された抗体およびそれらの結合体化方法 |
| ATE419008T1 (de) * | 2004-04-26 | 2009-01-15 | Innate Pharma | Adjuvante zusammensetzung und anwendungsverfahren dafür |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| EP1948195A2 (en) * | 2005-11-17 | 2008-07-30 | Innate Pharma | Improved methods of using phosphoantigen for the treatment of cancer |
| WO2008059052A1 (en) * | 2006-11-17 | 2008-05-22 | Innate Pharma | Improved methods of using phosphoantigen for the treatment of cancer |
| WO2009152440A1 (en) * | 2008-06-13 | 2009-12-17 | Cedars-Sinai Medical Center | Small molecule ligand-drug conjugates for targeted cancer therapy |
| WO2010049438A2 (en) * | 2008-10-30 | 2010-05-06 | Innate Pharma | Improved methods of using phosphoantigens for the treatment of diseases |
| ES2647317T3 (es) | 2008-11-03 | 2017-12-20 | Syntarga B.V. | Análogos de CC-1065 y sus conjugados |
| PT3056203T (pt) | 2010-04-21 | 2018-02-15 | Syntarga Bv | Conjugados de análogos de cc-1065 e ligantes bifuncionais |
| IT1401882B1 (it) | 2010-10-01 | 2013-08-28 | Rosa De | Nanoparticelle autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori. |
| HUE033704T2 (en) | 2012-02-13 | 2017-12-28 | Bristol Myers Squibb Co | Enediyne compounds, conjugates thereof, and uses and methods therefor |
| CN110947002A (zh) * | 2012-05-01 | 2020-04-03 | 约翰霍普金斯大学 | 治疗或预防骨关节炎的组合物和方法 |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| SG11201609372UA (en) | 2014-05-22 | 2016-12-29 | Synthon Biopharmaceuticals Bv | Site-specific conjugation of linker drugs to antibodies and resulting adcs |
| EP3368092B9 (en) | 2015-10-29 | 2020-07-29 | Novartis AG | Antibody conjugates comprising toll-like receptor agonist |
| CA3026139C (en) | 2016-02-12 | 2023-09-12 | Synthon Biopharmaceuticals B.V. | Selective reduction of cysteine-engineered antibodies |
| US11419944B2 (en) | 2016-10-11 | 2022-08-23 | Byondis B.V. | Non-linear self-immolative linkers and conjugates thereof |
| US11696958B2 (en) | 2017-05-23 | 2023-07-11 | Byondis B.V. | Dual conjugation process for preparing antibody-drug conjugates |
| WO2019182904A1 (en) | 2018-03-19 | 2019-09-26 | University Of Iowa Research Foundation | Phosphonamidate butyrophilin ligands |
| GB201810965D0 (en) | 2018-07-04 | 2018-08-15 | Univ College Cardiff Consultants Ltd | Phosphoantigen prodrug compounds |
| CA3110510A1 (en) | 2018-08-29 | 2020-03-05 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting egfr |
-
2022
- 2022-06-28 EP EP22740362.3A patent/EP4362982A1/en active Pending
- 2022-06-28 BR BR112023026735A patent/BR112023026735A2/pt unknown
- 2022-06-28 AU AU2022302784A patent/AU2022302784A1/en active Pending
- 2022-06-28 CN CN202280052486.6A patent/CN117794581A/zh active Pending
- 2022-06-28 MX MX2023014899A patent/MX2023014899A/es unknown
- 2022-06-28 IL IL309249A patent/IL309249A/en unknown
- 2022-06-28 KR KR1020247003259A patent/KR20240027761A/ko active Pending
- 2022-06-28 US US18/573,284 patent/US20240261426A1/en active Pending
- 2022-06-28 WO PCT/EP2022/067693 patent/WO2023275025A1/en not_active Ceased
- 2022-06-28 JP JP2023580402A patent/JP2024524363A/ja active Pending
- 2022-06-28 CA CA3223936A patent/CA3223936A1/en active Pending
-
2023
- 2023-12-26 CL CL2023003905A patent/CL2023003905A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240027761A (ko) | 2024-03-04 |
| CA3223936A1 (en) | 2023-01-05 |
| MX2023014899A (es) | 2024-04-29 |
| US20240261426A1 (en) | 2024-08-08 |
| AU2022302784A1 (en) | 2023-12-21 |
| BR112023026735A2 (pt) | 2024-03-12 |
| WO2023275025A1 (en) | 2023-01-05 |
| EP4362982A1 (en) | 2024-05-08 |
| JP2024524363A (ja) | 2024-07-05 |
| IL309249A (en) | 2024-02-01 |
| CN117794581A (zh) | 2024-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20230123A1 (ar) | تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها | |
| JOP20210074A1 (ar) | مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها | |
| JOP20210289A1 (ar) | مقترنات عقار - جسم مضاد مثبط لـmcl-1 وطرق لاستخدامها | |
| ECSP19044625A (es) | Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas | |
| CO2022007924A2 (es) | Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso | |
| CL2023003905A1 (es) | Conjugados novedosos que comprenden fosfoantígenos y su uso terapéutico | |
| MX2019005879A (es) | Enlazadores que contienen peptido para conjugados anticuerpo-farmaco. | |
| MX2019013690A (es) | Conjugados de farmaco-proteina con ciclodextrina. | |
| MX2021015974A (es) | Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados. | |
| CL2023000021A1 (es) | Fármacos enlazadores y conjugados de anticuerpo-fármaco antifolato. | |
| SA520420225B1 (ar) | cMET مترافقات عقار من عوامل رابطة أحادية النسيلة من واستخداماتها | |
| MX2025005811A (es) | Conjugados de anticuerpo ceacam5-fármaco y métodos de uso de los mismos | |
| UY38265A (es) | Conjugados anticuerpo droga para ablación de células madre hematopoyéticas | |
| MX2021003295A (es) | Enlazadores basados en sulfomaleimida y sus correspondientes conjugados. | |
| MX2024008269A (es) | Enlazador-fármacos de antifolato y conjugados de anticuerpo-fármaco. | |
| WO2019089594A8 (en) | Combination treatment with antibody-drug conjugates and cytarabine | |
| AR134425A1 (es) | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos | |
| DOP2025000322A (es) | Anticuerpos de nectina-4 y conjugados anticuerpo-fármaco | |
| PY24103486A (es) | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos | |
| AR130809A1 (es) | Conjugados de anticuerpo y fármaco que se dirigen a napi2b y métodos de uso | |
| PY2302747A (es) | Un anticuerpo endoédrico metalofullereno conjugado y usos del mismo | |
| PE20251274A1 (es) | Molecula de union dirigida a ror1 y uso de la misma | |
| EA202092951A1 (ru) | Конъюгаты антитела и лекарственного средства в качестве модулятора сплайсинга и способы их применения |